Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Metastatic Melanoma With KIT Aberrations
NCT01099514Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Aug 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in melanoma, sponsored by Samsung Medical Center. Primary endpoint: Response Rate. Started Aug 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01099514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01099514.